Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
about
Bortezomib for the treatment of multiple myelomaModulatory effects of bortezomib on host immune cell functionsAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Current and emerging treatment options for patients with relapsed myelomaThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.Update on the optimal use of bortezomib in the treatment of multiple myelomaBortezomib in multiple myeloma: systematic review and clinical considerations.Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.The risk factors for herpes zoster in bortezomib treatment in patients with multiple myelomaProteasome inhibition and its therapeutic potential in multiple myelomaBortezomib in the management of multiple myeloma.Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agentsPrimary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Proteasome inhibitors in the treatment of multiple myelomaThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaMultiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.The use of novel agents in the treatment of relapsed and refractory multiple myelomaInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Monoclonal gammopathy of undetermined significance and risk of infections: a population-based studyInduction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyProteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewOral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myelomaOphthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation.Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensHigh level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.Bortezomib for the treatment of non-Hodgkin's lymphomaMultiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologySecondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report.Clinical development of novel proteasome inhibitors for cancer treatment.Treatment of multiple myeloma in the targeted therapy era.
P2860
Q24185881-6F5FB867-82AD-48FA-8D4E-A90EBFB1C000Q26795618-6DDE192A-B041-45AA-B996-806CEE55563FQ26801716-573B39C6-FBF9-4C28-AAED-248206325C79Q26830878-E9B931CE-6654-48EE-A1EE-1BF37C383FD1Q28539605-664F60ED-605A-400F-BADF-28AE8FFD0A39Q29994527-04696D62-050C-4746-8A3A-4D40C96F122BQ33408049-DE941C20-6555-4BF4-89B6-2162AC4750E4Q33427726-250D4C83-7E0C-47B9-BA0B-F368EBAE4081Q33430998-0E0320E6-4DE0-4D5B-8D1F-1CD5F99AE215Q33440007-3F40BD1B-D3F9-48EF-A985-AAEEF8310A11Q33982728-15A34C58-20EB-4454-9952-D6D198937316Q34291012-13023094-444F-43E3-A030-EC8F499E6858Q34316960-D457F047-444C-4FB8-8180-F38BBC80FF9FQ34343036-F306E277-346C-483C-B3D0-399582E90802Q34418462-57904CA5-BE3A-4340-9D23-1D4D4BF0EF67Q34549211-7A4D717F-83C8-4E1B-ADFD-21038822266CQ34608608-CFF530F1-A471-4CC9-B7D6-FA750336A37FQ34611676-4D10EC45-189D-4F95-82FD-34BD60A4E3EFQ34707136-E83705DC-B211-4A0C-8CC6-2F552167FD70Q34798105-EEAD9F68-D511-4134-B03E-1550B8ED0FE6Q35066433-4E079903-AB43-47CD-A31F-D2EA0CD088A0Q35097319-CB12E069-E0CB-4A6F-8101-8ECFFDEF88B4Q35802414-778DC678-93C2-4423-86AA-FD8605F75077Q36006375-D0DAABF5-FD30-4D78-8CF4-10834C3E8CA3Q36060298-C63B5534-3ABE-4CA8-8352-E79FB91C1779Q36382493-032562A4-5094-434B-B2C3-016C551C7FADQ36408216-9D50F699-46A3-4067-9F3A-95D3B8E0DA60Q36524353-F120E6BB-A47A-480E-B7FE-3714759B6D23Q36525841-639912A7-BC22-4661-A393-3D8AE80DD9A2Q36544872-35A8C547-9463-4CA7-98CC-454E94BD41CAQ36604807-9FBF7840-9C80-4A71-8F53-0C07F987768FQ36703679-F26F6C42-003D-4E85-B658-9BE57316D0B9Q36705558-20601ECB-DE62-4C0F-A549-4B213FF72FE3Q36735810-7E7B8B04-3F1C-49B0-85BF-427707FC91C1Q36750576-9A024DD8-A4B3-4E6F-9CD3-0117F58A6FF5Q36868056-9FA7A091-AD5A-4692-B892-39B50858FEA2Q36963203-08F1D506-652D-4238-852B-496E64D65256Q37108758-482BB47F-E4BD-4360-B5B6-BAAC398F5C6CQ37136598-37E2C6DA-8888-43BD-A567-F8E7B2581C6EQ37385547-EF7A98DD-6296-4FF4-9585-B0E7F0E3F8E4
P2860
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Analysis of herpes zoster even ...... s in the phase III APEX study.
@en
Analysis of herpes zoster even ...... s in the phase III APEX study.
@nl
type
label
Analysis of herpes zoster even ...... s in the phase III APEX study.
@en
Analysis of herpes zoster even ...... s in the phase III APEX study.
@nl
prefLabel
Analysis of herpes zoster even ...... s in the phase III APEX study.
@en
Analysis of herpes zoster even ...... s in the phase III APEX study.
@nl
P2093
P50
P356
P1476
Analysis of herpes zoster even ...... s in the phase III APEX study.
@en
P2093
Asher Chanan-Khan
Dina Ben-Yehuda
Donna Reece
Edward A Stadtmauer
Jean-Luc Harousseau
Michael W Schuster
Rachel Neuwirth
P304
P356
10.1200/JCO.2007.14.9641
P407
P50
P577
2008-08-18T00:00:00Z